Breaking News Instant updates and real-time market news.

POST

Post Holdings

$96.51

1.73 (1.83%)

, SYK

Stryker

$168.57

1.735 (1.04%)

10:12
08/16/18
08/16
10:12
08/16/18
10:12

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Post Holdings (POST) initiated with an Overweight at Piper Jaffray. 2. Stryker (SYK) initiated with a Buy at BTIG. 3. Aveo Pharmaceuticals (AVEO) initiated with a Buy at H.C. Wainwright. 4. Uxin (UXIN) initiated with a Buy at Goldman Sachs. 5. AcelRx (ACRX) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

POST

Post Holdings

$96.51

1.73 (1.83%)

SYK

Stryker

$168.57

1.735 (1.04%)

AVEO

Aveo Pharmaceuticals

$2.26

0.085 (3.91%)

UXIN

Uxin

$5.58

0.315 (5.98%)

ACRX

AcelRx

$2.95

(0.00%)

  • 20

    Aug

  • 22

    Aug

  • 23

    Aug

  • 04

    Sep

  • 12

    Sep

POST Post Holdings
$96.51

1.73 (1.83%)

08/14/18
LEHM
08/14/18
INITIATION
Target $105
LEHM
Overweight
Post Holdings reinstated with an Overweight at Barclays
Barclays analyst Andrew Lazar reinstated coverage of Post Holdings with an Overweight rating and $105 price target. The analyst sees further share upside despite the 7.5% rally since the company's Q3 results on August 2 given its discount to peers, 5% free cash flow yield and "solid" EBITDA performance. Further, he believes Post's Private Brands transaction could "create additional creative actions to unlock value."
08/16/18
PIPR
08/16/18
INITIATION
Target $115
PIPR
Overweight
Post Holdings initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery initiated Post Holdings with an Overweight rating and $115 price target, telling investors in a research note that he expects continued strong top-line growth, both organic and from acquisitions. Lavery says he considers Post's portfolio "attractive," as cereal is a reliable cash generator, Active Nutrition is on-trend with consumers, and its refrigerated and foodservice business aligns well with consumer shifts to perimeter store and away-from-home food. Additionally, Lavery expects "steady" cash flow generation to continue, fueling debt pay-down, M&A, or opportunistic share repurchases.
06/27/18
VERF
06/27/18
DOWNGRADE
VERF
Hold
Post Holdings downgraded to Hold from Buy at Vertical Group
08/06/18
WELS
08/06/18
NO CHANGE
Target $111
WELS
Outperform
Post Holdings price target raised to $111 from $98 at Wells Fargo
Wells Fargo analyst John Baumgartner raised his price target for Post Holdings to $111 from $98 following a "very solid" Q3 despite headwinds. The analyst reiterates an Outperform rating on the shares.
SYK Stryker
$168.57

1.735 (1.04%)

08/16/18
BTIG
08/16/18
INITIATION
Target $187
BTIG
Buy
Stryker initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman initiated Stryker with a Buy rating and a price target of $187 as part of his broader research note titled "Riding the Robotic Wave in Orthopedics". The analyst cites the company's ability to generate consistent organic revenue growth across all its divisions at "multiples" of the broader medical technology market while also pointing to its "diversified revenue composition and consistency of execution". Despite the premium valuation, Zimmerman notes that Stryker is the stock to own over the long-term, adding that the company is also continually updating its product mix with strategic tuck-in acquisitions that leverage its sales channels.
07/25/18
RBCM
07/25/18
NO CHANGE
Target $184
RBCM
Outperform
Stryker price target raised to $184 from $175 at RBC Capital
RBC Capital analyst Glenn Novarro raised his price target on Stryker to $184 and kept his Outperform rating following the company's Q2 results. The analyst says Stryker "continues to deliver top-tier revenue growth" that is sustainable because of the company's product portfolio, pipeline, and M&A strategy. Novarro adds that the company's operating leverage also continues to improve, estimating a potential upside of up to 50bps in operating markets expansion for FY18.
07/25/18
CANT
07/25/18
NO CHANGE
Target $175
CANT
Neutral
Stryker price target raised to $175 from $170 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Stryker to $175 to reflect the company's organic growth beat in Q2 and the recent appreciation in sector valuations. Although Stryker continues to execute, its current valuation multiple and investor expectations "leave little room for upside in the stock relative to other large-cap medtech companies," Bijou tells investors in a research note. He reiterates a Neutral rating on the shares.
07/23/18
RHCO
07/23/18
NO CHANGE
Target $39
RHCO
Buy
Boston Scientific price target raised to $39 from $34 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Boston Scientific (BSX) to $39 and kept his Buy rating ahead of its Q2 results, saying that based on the pipeline and market opportunities discussed at the recent Endoscopy analyst meeting, a higher long-term assumption for the sector is warranted. Nudell expects the management to discuss the recent speculation about a proposed acquisition offer by Stryker (SYK), the U.S. Watchman momentum, and the opportunity of other products like Spectra WaveWriter, Vercise, Resonate w/HeartLogic, ACURATE, and the EP portfolio inclusive of DirectSense.
AVEO Aveo Pharmaceuticals
$2.26

0.085 (3.91%)

08/16/18
HCWC
08/16/18
INITIATION
Target $6.5
HCWC
Buy
Aveo Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated Aveo Pharmaceuticals (AVEO) with a Buy rating and $6.50 price target, citing the view that tivozanib offers potentially the "best-in-class" safety profile when compared to leading TKIs on the market, such as Pfizer's (PFE) Sutent and Bayer's (BAYRY) Nexavar. Ramakanth projects tivozanib to reach the U.S. market in 2020 and achieve risk-adjusted revenues of $651M by 2030.
07/19/18
PIPR
07/19/18
NO CHANGE
Target $5
PIPR
Overweight
Aveo Pharmaceuticals selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using the 32% selloff this week in shares of Aveo Pharmaceuticals as a buying opportunity. He reiterates an Overweight rating on the name with a $5 price target. The analyst views the pullback on news of data from the Phase III Tivo-3 trial of tivozanib in third-line renal cell carcinoma coming in Q4 as an overreaction. Tenthoff continues to believe Tivo-3 will be positive based on prior Tivo-1 progression-free survival benefit versus historical sorafenib. With positive Tivo-3 data, Aveo could respond to the 2013 tivozanib complete response letter with potential FDA approval next year, Tenthoff tells investors in a research note.
07/17/18
RILY
07/17/18
NO CHANGE
Target $5
RILY
Buy
Aveo data delay does not weaken conviction, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar says the delayed Tivo-3 data from Aveo Pharmaceuticals does not weaken his conviction in a positive readout. The analyst reiterates a Buy rating on the shares with a $5 price target following last night's disclosed. The stock in premarket trading is down 19%, or 55c, to $2.30.
03/29/18
PIPR
03/29/18
NO CHANGE
Target $5
PIPR
Overweight
Aveo Oncology should be bought ahead of Phase III data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Aveo Oncology to report Phase III Tivo-3 data in third-line renal cell carcinoma in Q2. The analyst is confident tivozanib will achieve a statistically significant survival benefit over Nexavar and recommeds buying the stock ahead of the readout. Positive data will enable Aveo to respond to the 2013 tivozanib complete response letter with potential FDA approval in 2019, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $5 price target.
UXIN Uxin
$5.58

0.315 (5.98%)

08/16/18
GSCO
08/16/18
INITIATION
Target $9.7
GSCO
Buy
Uxin initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Ronald Keung initiated Uxin with a Buy rating and $9.70 price target, stating that competition in the used car ecommerce sector in China remains intense but that he expects the company to remain a leader in the space. He projects Uxin to turn profitable by 2020, contingent on execution and continued consolidation of share in a market Keung sees as "non winner-takes-all."
07/30/18
JPMS
07/30/18
INITIATION
Target $9
JPMS
Neutral
Uxin initiated with a Neutral at JPMorgan
JPMorgan started Uxin with a Neutral rating and $9 price target.
07/23/18
MSCO
07/23/18
INITIATION
Target $14
MSCO
Overweight
Uxin initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Eddy Wang initiated Uxin with an Overweight rating and $14 price target, stating the he expects the company to strengthen its leading position in China's used car e-commerce market with its "seamlessly integrated online-offline business model."
ACRX AcelRx
$2.95

(0.00%)

06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
07/13/18
OPCO
07/13/18
INITIATION
OPCO
Perform
AcelRx initiated with a Perform at Oppenheimer
Oppenheimer analyst Leland Gershell initiated AcelRx with a Perform rating, citing regulatory uncertainty and commercial headwinds. In a note to investors, Gershell says that he "lacks conviction" on Dsuvia and Zalviso's ability to take meaningful share within the large acute pain/injectable opioid treatment market and that he is "cautious" in the near-term on Dsuvia's late-2018 FDA decision in a regulatory and societal atmosphere attuned to opioids' liabilities.
06/11/18
CANT
06/11/18
INITIATION
Target $6
CANT
Overweight
AcelRx initiated with an Overweight at Cantor Fitzgerald
Cantor initiated AcelRx with a Overweight and $6 price target.
08/16/18
LTCO
08/16/18
INITIATION
Target $7
LTCO
Buy
AcelRx initiated with a Buy at Ladenburg
Ladenburg analyst Michael Higgins initiated AcelRx with a Buy and $7 price target.

TODAY'S FREE FLY STORIES

WOLWF

Woolworths Group

$0.00

(0.00%)

18:51
01/21/19
01/21
18:51
01/21/19
18:51
Downgrade
Woolworths Group rating change at Citi »

Woolworths Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLESY

Lendlease Group

$0.00

(0.00%)

18:48
01/21/19
01/21
18:48
01/21/19
18:48
Upgrade
Lendlease Group rating change at Citi »

Lendlease Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$41.41

0.99 (2.45%)

17:56
01/21/19
01/21
17:56
01/21/19
17:56
Earnings
Enterprise Financial reports Q4 EPS $1.02, consensus 95c »

Reports Q4 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FB

Facebook

$150.01

1.77 (1.19%)

16:36
01/21/19
01/21
16:36
01/21/19
16:36
Periodicals
Facebook planning to add 1,000 jobs in Ireland by year-end, Reuters says »

Facebook will hire an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

FB

Facebook

$150.01

1.77 (1.19%)

16:33
01/21/19
01/21
16:33
01/21/19
16:33
Periodicals
Facebook's WhatsApp limits users to five text forwards, Reuters reports »

Facebook's WhatsApp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

ENB

Enbridge

$36.10

0.425 (1.19%)

16:28
01/21/19
01/21
16:28
01/21/19
16:28
Periodicals
Enbridge gas pipeline explosion creates fireball in Ohio, Reuters says »

An explosion of an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$160.76

3.48 (2.21%)

16:25
01/21/19
01/21
16:25
01/21/19
16:25
Periodicals
Linde Plc to launch $6B share buyback scheme, Reuters says »

Linde Plc said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HENKY

Henkel

$0.00

(0.00%)

16:01
01/21/19
01/21
16:01
01/21/19
16:01
Downgrade
Henkel rating change at Goldman Sachs »

Henkel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

$21.58

0.34 (1.60%)

14:06
01/21/19
01/21
14:06
01/21/19
14:06
Hot Stocks
Conagra exploring alternatives for Italian-based frozen pasta business »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

13:15
01/21/19
01/21
13:15
01/21/19
13:15
General news
IMF trimmed global growth amid "no-deal" Brexit and trade war concerns »

IMF trimmed global growth…

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$37.50

0.6 (1.63%)

, BA

Boeing

$364.79

5.52 (1.54%)

09:36
01/21/19
01/21
09:36
01/21/19
09:36
Hot Stocks
Air Lease announces lease placement of Boeing 737 MAX 9 »

Air Lease (AL) announced…

AL

Air Lease

$37.50

0.6 (1.63%)

BA

Boeing

$364.79

5.52 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 21

    Feb

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.